Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18792849 | Methods of administering safe colon cleansing compositions | August 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18743526 | Methods of administering safe colon cleansing compositions | June 2024 | December 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18711575 | INTRAVITREAL CORTICOSTEROID EXTENDED RELEASE IMPLANT AND METHODS OF USE | May 2024 | May 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18659629 | AQUEOUS LIQUID PREPARATION | May 2024 | January 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18425024 | GRANULATED AGRICULTURAL ADJUVANT AND METHOD OF MAKING AND USING SAME | January 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18360372 | GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEM | July 2023 | April 2025 | Abandon | 21 | 3 | 0 | Yes | No |
| 18336958 | TOBACCO LEAF FOLIAR SPRAYING SUBSTANCE AND METHOD FOR REDUCING HARMFUL INGREDIENTS IN CHEROOT AND TOBACCO SHREDS | June 2023 | March 2024 | Allow | 9 | 2 | 0 | No | No |
| 18189284 | SYSTEMS AND METHODS FOR APPLICATION OF ACTIVE INGREDIENTS TO CANNABIS | March 2023 | June 2024 | Abandon | 15 | 1 | 0 | No | No |
| 17985058 | DIVALENT METAL-CONTAINING BIOMATERIALS AND METHODS OF USE | November 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17968113 | USE OF TT-10-LOADED NANOPARTICLES FOR CARDIAC REPAIR | October 2022 | October 2024 | Abandon | 24 | 1 | 0 | No | No |
| 18045059 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | October 2022 | May 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17951986 | USE OF 4-(PHENYLETHYNYL) BENZOIC ACID | September 2022 | March 2024 | Allow | 18 | 2 | 0 | No | No |
| 17935065 | Low Viscosity Agricultural Adjuvant for Spraying Syrups and Method of Production | September 2022 | May 2024 | Allow | 20 | 1 | 0 | No | No |
| 17950612 | NOVEL CERIUM OXIDE NANOCOMPLEX AND A COMPOSITION FOR PREVENTING OR TREATING LIVER FAILURE COMPRISING THE SAME | September 2022 | August 2024 | Allow | 23 | 3 | 0 | No | No |
| 17933929 | COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTS | September 2022 | April 2025 | Allow | 31 | 1 | 0 | No | No |
| 17903597 | Ocular surface drug retention agent, eye drop containing the same, and method for retention of ocular surface drug using the same and method for treating ocular disease | September 2022 | June 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 17876811 | PHOTOCURABLE HYDROGEL LOADED WITH VH298-MODIFIED EXOSOME AND METHOD OF PREPARATION AND USE THEREOF | July 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17787603 | COMPOSITION FOR PREVENTING OR TREATING OCULAR DISEASES COMPRISING AMNIOTIC EPITHELIAL CELL DERIVED EXOSOMES | June 2022 | May 2025 | Allow | 35 | 1 | 0 | No | No |
| 17833019 | APPLICATION OF ENDOPHYTIC FALCIPHORA ORYZAE FO-R20 IN CONTROLLING PANICLE BLAST | June 2022 | February 2024 | Allow | 21 | 1 | 0 | No | No |
| 17658644 | PHYTOREGULATOR FOR PLANTS | April 2022 | April 2025 | Abandon | 37 | 3 | 0 | No | No |
| 17767804 | AGROCHEMICAL COMPOSITION | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17656825 | Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders | March 2022 | February 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17702885 | GERMINATION/SPROUTING AND FRUIT RIPENING REGULATORS | March 2022 | September 2024 | Allow | 30 | 2 | 1 | No | No |
| 17636651 | SYNERGISTIC HPPD MIXTURES | February 2022 | June 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17632152 | AQUEOUS FORMULATION THAT REDUCES DAMAGE CAUSED BY SPRING FROSTS IN PLANTS AND PRODUCTION METHOD THEREOF | February 2022 | February 2024 | Allow | 24 | 1 | 0 | No | No |
| 17649469 | RHEOLOGY MODIFIED LOW FOAMING LIQUID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | January 2022 | November 2024 | Allow | 33 | 2 | 0 | No | No |
| 17582886 | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy | January 2022 | January 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17629267 | PROCESS FOR THE PREPARATION OF STERILE OPHTHALMIC AQUEOUS FLUTICASONE PROPIONATE FORM A NANOCRYSTALS SUSPENSIONS | January 2022 | April 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17580770 | Seed Coating | January 2022 | October 2024 | Allow | 33 | 3 | 0 | No | No |
| 17626313 | MIXTURES COMPRISING INDAZOLE PESTICIDES | January 2022 | May 2025 | Allow | 40 | 1 | 1 | No | No |
| 17622677 | USE OF DIHYDROPORPHIN DERIVED FROM CHLOROPHYLL AS PLANT GROWTH REGULATOR | December 2021 | December 2024 | Allow | 36 | 2 | 0 | No | No |
| 17622576 | MELANOIDIN COMPOSITIONS FOR PROTECTING CROPS FROM NONFUNGAL PESTS | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17619311 | STABLE HERBICIDAL COMPOSITIONS COMPRISING AMINE OXIDE AND BETAINE | December 2021 | June 2025 | Allow | 42 | 1 | 1 | No | No |
| 17619565 | PHARMACEUTICAL COMPOSITION COMPRISING A COLLOIDAL DISPERSION AND METHODS AND USES THEREOF | December 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17618931 | FORMULATIONS AND METHODS FOR CONTROLLING INVASIVE AMPHIBIANS | December 2021 | April 2025 | Allow | 40 | 2 | 0 | No | No |
| 17618531 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | December 2021 | May 2025 | Allow | 41 | 1 | 1 | No | No |
| 17533862 | PROCESSES AND COMPOSITIONS FOR INCREASING ENZYME CONCENTRATIONS AND DRY MATTER USING REACTIVE OXYGEN SPECIES IN HYDROPONICALLY GROWN CELLULOSIC MATERIALS | November 2021 | March 2025 | Abandon | 40 | 3 | 0 | No | No |
| 17612551 | Vancomycin Liposome Compositions and Methods | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17525170 | HIGH-PURITY THERMOSTABLE CRYSTAL FORM OF SUBSTITUTED 3-ISOXAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | November 2021 | September 2024 | Allow | 34 | 1 | 0 | No | No |
| 17610263 | HERBICIDAL COMPOSITION | November 2021 | December 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17516845 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | November 2021 | November 2024 | Allow | 36 | 1 | 0 | No | No |
| 17507593 | PRESERVATIVE REMOVAL FROM EYE DROPS | October 2021 | September 2024 | Allow | 35 | 2 | 0 | No | No |
| 17505029 | Methods and Compositions for Treating Ulcerative Colitis | October 2021 | December 2024 | Allow | 38 | 2 | 0 | No | No |
| 17604892 | ESTERS OF NON- AROMATIC HETEROCYCLIC COMPOUNDS HAVING A NEMATOCIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17501854 | SUPER-RESOLUTION OPTICAL MICROSCOPY USING ALUMINOSILICATE NANOPARTICLES | October 2021 | August 2024 | Allow | 34 | 1 | 1 | No | No |
| 17600897 | PYRIDAZINONE COMPOUND AND HERBICIDE | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17491687 | PEROXIDE-LESS BIOPHOTONIC COMPOSITIONS AND METHODS | October 2021 | December 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17486308 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLURBIPROFEN | September 2021 | May 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17593749 | SUBSTITUTED 2-HETEROARYLAMINOBENZENES AND THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | September 2021 | May 2025 | Allow | 44 | 2 | 1 | No | No |
| 17441748 | METHOD FOR CONTROLLING WEEDS | September 2021 | February 2025 | Allow | 41 | 2 | 0 | No | No |
| 17441722 | METHOD FOR CONTROLLING WEEDS | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17593615 | FRUIT BLOSSOM END ROT-PREVENTING AGENT COMPRISING NITROPHENOL COMPOUND OR SALT THEREOF | September 2021 | May 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17448151 | Facile Assembly of Soft Nanoarchitectures and Co-Loading of Hydrophilic and Hydrophobic Molecules via Flash Nanoprecipitation | September 2021 | August 2024 | Allow | 35 | 1 | 0 | No | No |
| 17439455 | Aqueous 1,2-Benzisothiazoline-3-One Dispersions | September 2021 | September 2024 | Allow | 36 | 1 | 0 | No | No |
| 17438871 | NOVEL 3-(2-BROMO-4-ALKYNYL-6-ALKOXYPHENYL)-3-PYRROLIN-2-ONES AND THEIR USE AS HERBICIDES | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17593100 | SOIL MICROBIAL REGULATOR FOR ENHANCING PLANT STRESS RESISTANCE | September 2021 | December 2024 | Allow | 39 | 2 | 0 | No | No |
| 17465546 | TOPICAL SANITIZING FORMULATIONS AND USES THEREOF | September 2021 | August 2024 | Allow | 35 | 1 | 0 | No | No |
| 17465748 | Solid Implant Formulation for Drug Delivery | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17410523 | COMPOSITIONS AND METHODS OF MODULATING ENDOCHONDRAL OSSIFICATION AND BONE FORMATION | August 2021 | October 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17411044 | PERAMIVIR SOLUTION TYPE INHALANT AND PREPARATION METHOD THEREFOR | August 2021 | October 2024 | Allow | 37 | 1 | 0 | No | No |
| 17431815 | PYRIDAZINES HERBICIDAL COMPOUNDS | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17431294 | PROTOPORPHYRIN IX DERIVATIVES AND USE THEREOF TO IMPROVE THE HEALTH OF PLANTS | August 2021 | September 2024 | Allow | 37 | 1 | 0 | No | No |
| 17430411 | HERBICIDAL COMPOSITIONS | August 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17428433 | HERBICIDAL COMPOUNDS | August 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17391495 | Oral Rapamycin Nanoparticle Preparations and Use | August 2021 | October 2024 | Allow | 39 | 1 | 0 | No | No |
| 17388066 | NANOPARTICLES FOR USE AS A THERAPEUTIC VACCINE | July 2021 | May 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17386762 | SYSTEMS AND METHODS FOR TREATING AND/OR PREVENTING ACNE | July 2021 | March 2025 | Allow | 43 | 4 | 0 | No | No |
| 17385480 | MEDICAL AND NUTRITIONAL COMPOSITIONS AND METHODS OF USE | July 2021 | March 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17381464 | TREATMENT OF SYMPTOMS ASSOCIATED WITH FEMALE GASTROPARESIS | July 2021 | June 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17378309 | COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USE | July 2021 | August 2024 | Allow | 37 | 1 | 0 | No | No |
| 17361995 | NOVEL FORMULATION AND TREATMENT METHODS | June 2021 | June 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17304708 | Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders | June 2021 | September 2021 | Allow | 3 | 1 | 0 | No | No |
| 17417326 | METHOD FOR CONTROLLING WEED | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17304289 | DOSAGE FORM OF VINCA ALKALOID DRUG | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17343471 | AMORPHOUS CALCIUM CARBONATE STABILIZED WITH POLYPHOSPHATES OR BISPHOSPHONATES | June 2021 | June 2024 | Allow | 36 | 1 | 0 | No | No |
| 17299409 | METHYLOBACTERIUM COMPOSITIONS FOR IMPROVING CORN YIELD | June 2021 | June 2025 | Allow | 48 | 1 | 1 | No | No |
| 17299724 | HERBICIDAL COMPOSITIONS | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17319292 | COMPOSITIONS OF AMORPHOUS CALCIUM CARBONATE FOR INHALATION, SUBLINGUAL OR BUCCAL ADMINISTRATION | May 2021 | June 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17236054 | ORAL SOLUBLE FILM CONTAINING SILDENAFIL CITRATE | April 2021 | September 2021 | Allow | 5 | 2 | 0 | No | No |
| 17285813 | HETEROARYLAMINOQUINOLINES AND ANALOGUES | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17206890 | METHODS FOR TREATING OCULAR INFLAMMATORY DISEASES | March 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17204743 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISM | March 2021 | August 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17200595 | PRESERVATIVE REMOVAL FROM EYE DROPS | March 2021 | July 2021 | Allow | 4 | 1 | 0 | No | No |
| 17183553 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | February 2021 | October 2021 | Allow | 8 | 2 | 0 | No | No |
| 17249238 | Zeaxanthin Formulations With Additional Ocular-Active Nutrients,For Protecting Eye Health And Treating Eye Disorders | February 2021 | May 2021 | Allow | 3 | 1 | 0 | No | No |
| 17179650 | KETOROLAC COMPOSITIONS FOR CORNEAL WOUND HEALING | February 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17173229 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | February 2021 | October 2023 | Allow | 32 | 2 | 0 | No | No |
| 17171624 | COMPOSITIONS AND METHODS FOR REDUCING BODY FAT | February 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17148236 | VETERINARY PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTION | January 2021 | February 2024 | Allow | 37 | 1 | 0 | No | No |
| 17067977 | ENCAPSULATION OF HERBICIDES TO REDUCE CROP INJURY | October 2020 | December 2024 | Allow | 51 | 4 | 0 | Yes | No |
| 17011888 | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy | September 2020 | July 2021 | Allow | 10 | 2 | 0 | No | No |
| 16087757 | CONTROLLED PRODUCTION OF SPHERICAL CALCIUM PHOSPHATE, MAGNESIUM PHOSPHATE, AND STRONTIUM PHOSPHATE PARTICLES FOR DENTAL AND ORTHOPEDIC APPLICATIONS USING DUAL ASYMMETRIC CENTRIFUGATION | August 2020 | September 2021 | Allow | 36 | 1 | 0 | No | No |
| 16929837 | COMPOSITIONS OF AMORPHOUS CALCIUM CARBONATE FOR INHALATION, SUBLINGUAL OR BUCCAL ADMINISTRATION | July 2020 | February 2021 | Allow | 7 | 1 | 0 | No | No |
| 16907726 | COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USE | June 2020 | March 2021 | Allow | 9 | 1 | 0 | No | No |
| 16892592 | NOVEL OCCLUSIVE COMPOSITIONS | June 2020 | November 2021 | Allow | 18 | 1 | 0 | No | No |
| 16769057 | EYE MAKE-UP COMPOSITIONS COMPRISING GRAPHENE | June 2020 | November 2021 | Allow | 18 | 2 | 0 | No | No |
| 16877986 | PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTION | May 2020 | October 2020 | Allow | 5 | 1 | 0 | No | No |
| 16762170 | DENTAL COMPOSITION WITH HIGH E-MODULUS | May 2020 | October 2020 | Allow | 6 | 0 | 0 | No | No |
| 16868918 | FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE | May 2020 | June 2021 | Allow | 13 | 1 | 0 | No | No |
| 16867319 | POLYFUNCTIONAL RADICAL SCAVENGER HYDROGEL FORMULATION | May 2020 | April 2021 | Allow | 12 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FAY, ZOHREH ALEMZADEH.
With a 21.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FAY, ZOHREH ALEMZADEH works in Art Unit 1617 and has examined 422 patent applications in our dataset. With an allowance rate of 66.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner FAY, ZOHREH ALEMZADEH's allowance rate of 66.8% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by FAY, ZOHREH ALEMZADEH receive 1.96 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FAY, ZOHREH ALEMZADEH is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -4.1% benefit to allowance rate for applications examined by FAY, ZOHREH ALEMZADEH. This interview benefit is in the 4% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 21.3% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 48.5% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 44.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 48.1% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 78.1% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 31.9% of allowed cases (in the 96% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.